Jean‐Valère Malfuson

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 276 citations · Full text

Medicine, Oncology, Hematologic Oncology +8

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Emmanuel Raffoux, Audrey Cras, Christian Récher et al. · Oncotarget · 2010 · 134 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Cédric Rossi, Julia Gilhodes, Marie Maerevoet et al. · American Journal of Hematology · 2018 · 122 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Élise Fournier, Nicolas Duployez, Benoît Ducourneau et al. · Blood · 2019 · 87 citations · Full text

Medicine, Hematology, Oncology +16

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Claude Gardin, Cécile Pautas, Élise Fournier et al. · Blood Advances · 2020 · 84 citations · Full text

Life Sciences, Genetics, Oncology +14